FindTrial
Sign In

A study for efficacy of thalidomide in non-transfusion dependent thalassemia patients

A non-randomized interventional study of thalidomide and hydroxyurea in children with non-transfusion dependent thalassemia - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/05/068148
Enrollment
30
Registered
2024-05-31
Start date
Unknown
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D561- Beta thalassemia

Interventions

Intervention1: Thalidomide: Thalidomide will be added at a dose of 2-2.5 mg/kg/day in patients with NTDT(non-transfusion dependent thalassemia) on hydroxyurea. Intervention2: Thalidomide: Thalidomide

Sponsors

Thalassemic charitable trust
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. All patients with non-transfusion dependent thalassemia on hydroxyurea for at least 12 months.

Exclusion criteria

Exclusion criteria: 1. Lack of consent 2. systemic illness- renal, hepatic or neurological. 3. HIV, HBV, HCV infection

Design outcomes

Primary

MeasureTime frame
To compare the change in hemoglobin levels of the combination of thalidomide and hydroxyurea in patients with NTDT.Timepoint: 6 months—

Secondary

MeasureTime frame
adverse effects of thalidomideTimepoint: 6 months;change in HbF levelsTimepoint: 6 months;Change in spleen sizeTimepoint: 6 months—

Countries

India

Contacts

Public ContactDr Thakkar Malav Pareshbhai

PGIMER chandihgarh

deepakbansaldr@gmail.com0172-2755317

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026